Lilly Cost-Cutting Program Will Eliminate 1,000 Positions
This article was originally published in The Pink Sheet Daily
Executive Summary
The restructuring program will affect R&D, manufacturing and sales & marketing. The program is expected to be completed by Mach 31, 2005, and will result in net savings of $150 mil. for 2005. Lilly’s third quarter sales rose 4% to $3.28 bil.
You may also be interested in...
Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said
Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic
Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said
Lilly Updates On Cymbalta, Zyprexa, Cialis Expected At Dec. 9 Meeting
Cymbalta was launched for depression in August; Lilly anticipates first half 2005 approval of duloxetine for stress urinary incontinence under the Yentreve name. Patent challenges to the antipsychotic Zyprexa and Lilly’s cost-cutting efforts are also likely topics at the investor meeting.